Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.31 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 3/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16437138 | 0.92 | ADORA3 (0.37) | KDM4ESMN1; SMN2CYP3A4 | |
| SCHEMBL17804245 | 0.91 | SMN1; SMN2 (0.36) | L3MBTL1MAPTRAB9ASMN1; SMN2HPGD | |
| SCHEMBL17614602 | 0.89 | CREBBP (0.31) | KDM4ESMN1; SMN2POLBHPGDALDH1A1 | |
| SCHEMBL17796907 | 0.87 | MEN1 (0.34) | MAPTRAB9ASMN1; SMN2POLBTSHR | |
| SCHEMBL17811641 | 0.86 | BRD9 (0.34) | MAPTBRD9BRD7 | |
| SCHEMBL17804259 | 0.86 | BRD9 (0.33) | BRD9BRD7 | |
| SCHEMBL17811645 | 0.86 | GRM2 (0.32) | — | |
| SCHEMBL17804254 | 0.86 | PDCD1 (0.34) | MAPTRAB9AHPGDALDH1A1TSHR | |
| SCHEMBL17799626 | 0.85 | KCNN4 (0.36) | L3MBTL1KDM4ESMN1; SMN2HPGDTSHR | |
| SCHEMBL17804238 | 0.84 | BRD9 (0.37) | MAPTGAABRD9BRD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9521848-B2 | Tetrazolinone compound and use therefor | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-12-20 | — | — | US | disclosed |
| US-20160157489-A1 | TETRAZOLINONE COMPOUND AND USE THEREFOR | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160157489-A1 | TETRAZOLINONE COMPOUND AND USE THEREFOR | CYP51A1, CYP4F11, CYP1B1 | L3MBTL1 738/4885MAPT 2890/4885GAA 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.